(Q36675417)

15 August 2017

1 reference

title

Abacavir/lamividune combination in the treatment of HIV-1 infection: a review (English)

1 reference

15 August 2017

Laura Waters

1

1 reference

PubMed ID

17150010

15 August 2017

Graeme Moyle

series ordinal

2

1 reference

PubMed ID

17150010

15 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

1 reference

15 August 2017

7

1 reference

15 August 2017

18

1 reference

15 August 2017

2571-2580

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Stevens-Johnson syndrome in HIV patients treated with nevirapine: two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Pharmacodynamics of abacavir in an in vitro hollow-fiber model system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.18.2571

10.1517/14656566.7.18.2571

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17150010